RT Journal Article
T1 Delftibactin-A, a Non-ribosomal Peptide With Broad Antimicrobial Activity.
A1 Tejman-Yarden, Noa
A1 Robinson, Ari
A1 Davidov, Yaakov
A1 Shulman, Alexander
A1 Varvak, Alexander
A1 Reyes, Fernando
A1 Rahav, Galia
A1 Nissan, Israel
K1 Delftia
K1 antimicrobial
K1 delftibactin-A
K1 new antibiotic
K1 siderophore
AB The rapid emergence of drug resistant bacteria is occurring worldwide, outpacing the development of new antibiotics. It is known that some of the main sources of antibiotics are the bacteria themselves, many of which are secondary metabolites of Gram positive bacteria. Siderophores, which are secondary metabolites, function as natural chelators (e.g., iron). They are produced and secreted by many bacteria and have been experimented on as "carriers" of several types of antibiotics that pass the cell membrane of challenging Gram negative bacteria. Delftibactin A is a non-ribosomal peptide (NRP), which is known to detoxify gold in Delftia spp. and form gold nuggets, and is considered to be a siderophore. In this study we demonstrate that the supernatant from novel environmental isolates of Delftia spp. have antimicrobial activity. We characterized the active fraction and identified delftibactin A as a compound with antimicrobial activity. Delftibactin A exhibits potent antimicrobial activity against Gram positive multi drug resistant (MDR) bacteria like Methicillin-resistant Staphylococcus aureus (MRSA), and Vancomycin resistant Enterococcus (VRE), and also against the Gram negative pathogens Acinetobacter baumannii and Klebsiella pneumoniae. We discovered that the production of delftibactin A is greatly influenced by temperature. Furthermore, we have demonstrated the possibility of utilizing delftibactin A as a siderophore carrier of toxic metals such as gallium into Gram negative bacteria. These findings expose new opportunities of yet unexploited natural products such as delftibactin A, which have been known for other bacterial uses, as potent factors in the battle against MDR bacteria.
SN 1664-302X
YR 2019
FD 2019-10-15
LK http://hdl.handle.net/10668/14624
UL http://hdl.handle.net/10668/14624
LA en
DS RISalud
RD Apr 5, 2025